Our market reports now include the latest updates on global tariffs, trade impacts, and evolving supply chain dynamics.
How has the warm autoimmune hemolytic anemia (waiha) treatment market size changed in recent years, and what is the outlook ahead?
The warm autoimmune hemolytic anemia (WAIHA) treatment market size has grown strongly in recent years. It will grow from $0.55 billion in 2024 to $0.60 billion in 2025 at a compound annual growth rate (CAGR) of 9.7%. The growth in the historic period can be attributed to rising healthcare expenditure, increasing clinical trials focused on rare hematologic diseases, growing patient support and advocacy networks, and rising geriatric population.
The warm autoimmune hemolytic anemia (WAIHA) treatment market size is expected to see strong growth in the next few years. It will grow to $0.87 billion in 2029 at a compound annual growth rate (CAGR) of 9.5%. The growth in the forecast period can be attributed to increasing prevalence of autoimmune disorders, growing awareness among healthcare professionals, rising adoption of biologics and targeted therapies, and growing use of off-label drugs in autoimmune conditions. Major trends in the forecast period include advancements in monoclonal antibody therapies, integration of next-generation sequencing (NGS) in diagnostics, advancements in immunology research, and technology-enabled drug discovery platforms.
Download Your Free Sample PDF:
https://www.thebusinessresearchcompany.com/sample.aspx?id=24426&type=smp
What are the top economic and technological drivers pushing warm autoimmune hemolytic anemia (waiha) treatment market growth?
The increasing healthcare expenditure is projected to fuel the growth of the warm autoimmune hemolytic anemia (WAIHA) treatment market going forward. Healthcare expenditure refers to the total amount of resources spent on health services, including prevention, diagnosis, treatment, and management of diseases, by individuals, governments, and organizations. Advancements in medical technology are driving up healthcare expenditure, as newer diagnostic tools and treatments often come with higher costs for development, implementation, and ongoing patient care. Healthcare expenditure supports warm autoimmune hemolytic anemia (WAIHA) treatment by funding research, providing access to advanced diagnostic tools, and ensuring the availability of specialized therapies that help manage and control the disease. For instance, in May 2024, according to the Office for National Statistics, a UK-based government agency, in real terms, long-term health and social care expenditures increased by 2.8% in 2022, but overall healthcare spending increased by 5.6% in 2023. Therefore, the increasing healthcare expenditure is driving the growth of the warm autoimmune hemolytic anemia (WAIHA) treatment market.
How is the warm autoimmune hemolytic anemia (waiha) treatment market segmented by product, application, and end-user?
The warm autoimmune hemolytic anemia (WAIHA) treatment market covered in this report is segmented –
1) By Treatment Type: Corticosteroids, Monoclonal Antibodies, Intravenous Immunoglobulin (IVIG), Blood Transfusions, Splenectomy
2) By Route Of Administration: Oral, Intravenous, Subcutaneous
3) By Patient Demographics: Children, Adults, Geriatric
4) By Therapeutic Area: Primary Autoimmune Disorders, Secondary Autoimmune Disorders, Genetic Predisposition
5) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
Subsegments:
1) By Corticosteroids: Prednisone, Dexamethasone, Methylprednisolone
2) By Monoclonal Antibodies: Rituximab, Sutimlimab, Bortezomib
3) By Intravenous Immunoglobulin: Standard IVIG, High-Dose IVIG Therapy, Pooled Plasma-Derived Immunoglobulins
4) By Blood Transfusions: Leukoreduced RBC Transfusions, Emergency Transfusions, Phenotypically Matched RBC Transfusions
5) By Splenectomy: Laparoscopic Splenectomy, Prophylactic Treatments Post-Splenectomy, Open Splenectomy
View The Full Market Report:
What technological trends are expected to redefine the warm autoimmune hemolytic anemia (waiha) treatment market?
Major companies operating in the warm autoimmune hemolytic anemia (WAIHA) treatment market are focusing on developing innovative solutions, such as monoclonal antibodies, to address the unmet clinical needs and improve patient outcomes. Monoclonal antibodies are lab-engineered proteins that target specific immune cells or pathways to reduce the destruction of red blood cells in warm autoimmune hemolytic anemia. For instance, in July 2023, IASO Biotechnology, a China-based biopharmaceutical company, announced the U.S. Food and Drug Administration (FDA) approval for IASO-782 Injection for use in clinical studies for autoimmune hematological conditions in the United States, such as warm autoimmune hemolytic anemia (WAIHA) and primary immune thrombocytopenia (ITP). Targeting CD19, this fully human monoclonal antibody has Fc mutations to increase ADCC activity while maintaining other Fc functions. It selectively depletes CD19+ B cells, plasma blasts, and some plasma cells, which are responsible for producing auto-reactive antibodies. Due to its distinct mechanism, IASO-782 may be used to treat autoimmune illnesses that are caused by pathogenic B and plasma cells, such as ITP and AIHA.
Which leading companies are dominating the warm autoimmune hemolytic anemia (waiha) treatment market landscape?
Major companies operating in the warm autoimmune hemolytic anemia (WAIHA) treatment market are Johnson & Johnson, F. Hoffmann-La Roche Ltd., Sanofi S.A., AstraZeneca Plc, Novartis AG, Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., Agios Pharmaceuticals Inc., Incyte corporation, Mallinckrodt Pharmaceuticals, Hutchison Medipharma Limited, BioCryst Pharmaceuticals Inc., Xencor Inc., Annexon Inc., Rigel Pharmaceuticals Inc., Apellis Pharmaceuticals Inc., Momenta Pharmaceuticals Inc., Immunovant Inc., Zenas BioPharma Inc., Alexion Pharmaceuticals Inc., Mitsubishi Tanabe Pharma Corporation.
Which geographic areas are expected to offer the highest growth opportunities in thewarm autoimmune hemolytic anemia (waiha) treatment market?
North America was the largest region in the warm autoimmune hemolytic anemia (WAIHA) treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the warm autoimmune hemolytic anemia (WAIHA) treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
How Can Companies Use The Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment Market Report to Drive Business Results?
This report provides actionable insights tailored for business use—not academic analysis. Companies can leverage the data to:
• Time market entry or expansion using growth forecasts and CAGR trends.
• Develop competitive products by tracking key technology shifts and user preferences.
• Tailor regional strategies with in-depth geographic data and local market dynamics.
• Benchmark and plan partnerships using competitive landscape insights.
Purchase The Report And Get A Swift Delivery:
https://www.thebusinessresearchcompany.com/customise?id=24426&type=smp
Need Customized Data On Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment Market?
For companies needing more tailored intelligence, The Business Research Company offers customized consulting and data services. Whether you’re entering new regions, launching innovative products, or assessing M&A opportunities, our experts can develop actionable insights specific to your business objectives.
Request Customized Data:
https://www.thebusinessresearchcompany.com/sample.aspx?id=24426&type=smp
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
https://thebusinessresearchcompany.com/
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
